Simeprevir

Revision as of 18:54, 20 March 2015 by Turky Alkathery (talk | contribs) (Reverted edits by Turky Alkathery (talk) to last revision by ShiSheng)
Jump to navigation Jump to search
Simeprevir
OLYSIO® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Medivir and Johnson & Johnson's pharmaceutical division Janssen Pharmaceutica. In the United States, simeprevir is approved by the Food and Drug Administration for use in combination withpeginterferon-alfa and ribavirin.[1] Simeprevir has been approved in Japan for the treatment of chronic hepatitis C infection, genotype 1.[2]

Category

Antiviral

US Brand Names

OLYSIO®

FDA Package Insert

Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages

Mechanism of Action

References

  1. ↑ "FDA approves new treatment for hepatitis C virus". Food and Drug Administration. Nov 22, 2013.
  2. ↑ "Medivir: Simeprevir has been approved in Japan for the treatment of genotype 1 chronic hepatitis C infection". The Wall Street Journal. September 27, 2013.
Retrieved from "https://www.wikidoc.org/index.php?title=Simeprevir&oldid=1078747"